drugset / Trial / NCT04998747
A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Non-randomizedSequentialOpen-labelBasic science
Summary
A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)
Timeline
- Start
- 2023-08-29
- Primary completion
- 2025-08-02
- Completion
- 2025-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pavurutamab | Protein / enzyme biologic | — | Subcutaneous |